Connect with us

News

Korsana raises US$175m for Alzheimer’s therapy

Published

on

Korsana Biosciences has emerged from stealth with US$175m to develop an Alzheimer’s antibody designed to boost amyloid plaque clearance.

The Waltham, Massachusetts-based biotech is focused on neurodegenerative disease.

Its lead programme, KRSA-028, is a next-generation shuttled monoclonal antibody targeting amyloid beta, a protein that can build up into plaques in Alzheimer’s.

The treatment uses the company’s THETA platform, which incorporates transferrin receptor (TfR1) and Fc engineering to improve delivery across the blood-brain barrier, the protective layer that controls what enters the brain from the bloodstream.

The company says KRSA-028 is designed to increase plaque clearance, lower the rate of amyloid-related imaging abnormalities (ARIA), changes seen on brain scans, and support low-volume subcutaneous dosing, given under the skin, rather than intravenous infusions.

The company was founded in 2024 with a US$25m seed investment and closed a US$150m Series A financing round in September 2025.

It has appointed Jonathan Violin as president and chief executive. Dr Violin has been a venture partner at Fairmount since 2023 and previously served as founding chief executive of Viridian Therapeutics from 2020 to 2023.

He was also founding chief executive of Dianthus Therapeutics and Quellis Biosciences, which merged into Astria Therapeutics.

Dr Violin said: “We are thrilled to announce the launch of Korsana with a mission to elevate expectations for patients suffering from devastating neurodegenerative diseases.

“In particular, Alzheimer’s disease represents a massive and growing unmet need, with the US patient population projected to double to approximately 13m by 2050.

“Only two disease-modifying therapies have been approved to treat Alzheimer’s, and both carry safety warnings, offer only modest efficacy, and impose a high burden of care.

“Patients deserve better options than what is currently available, and we believe our lead programme KRSA-028 can deliver a best-in-class product to treat Alzheimer’s.

“I am thrilled with the robust support of our mission by Korsana’s investors, and excited to build another leading biotechnology company in partnership with the team at Paragon Therapeutics.”

The Series A was co-led by Wellington Management and TCGX, with participation from J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital and others.

The seed round came from Fairmount and Venrock Healthcare Capital Partners.

KRSA-028 was discovered in partnership with Paragon Therapeutics. The company is also advancing a pipeline of THETA-enabled therapies for other undisclosed neurodegenerative diseases.

The financing is expected to fund activities into 2028, including pharmacokinetics, CNS penetration and safety data from healthy volunteers expected in mid-2027, and initial proof-of-concept data showing amyloid plaque clearance in Alzheimer’s patients expected by the end of 2027.

Andrew Gottesdiener, partner at Venrock and co-founder and member of the board of directors of Korsana, said: “We believe Korsana is well positioned to overcome the limitations of not just first-generation Alzheimer’s therapies, but also of earlier shuttle technologies.

“Leveraging a well-established regulatory pathway, Korsana is advancing the next generation of therapies for Alzheimer’s disease and other neurodegenerative disorders, with a clear path to creating value for patients.

“We are thrilled to work with Korsana to build what I believe will become an important and valuable company. Together, we are committed to delivering better medicines to patients suffering from neurodegenerative diseases.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

News

AI can predict Alzheimer’s with almost 93% accuracy, researchers say

Published

on

Alzheimer’s AI can predict the disease with nearly 93 per cent accuracy using more than 800 brain scans, researchers say.

The system identified anatomical changes in the brain linked to the onset of the most common form of dementia, a condition that gradually damages memory and thinking.

The findings build on years of research suggesting AI could help spot early Alzheimer’s risk, predict disease and identify patients whose condition has not yet been diagnosed.

Benjamin Nephew, an assistant research professor at the Worcester Polytechnic Institute in Massachusetts, said: “Early diagnosis of Alzheimer’s disease can be difficult because symptoms can be mistaken for normal ageing.

“We found that machine-learning technologies, however, can analyse large amounts of data from scans to identify subtle changes and accurately predict Alzheimer’s disease and related cognitive states.”

The study used MRI scans, a type of detailed brain imaging, from 344 people aged 69 to 84.

The dataset included 281 scans showing normal mental function, 332 with mild cognitive impairment, an early stage of memory and thinking decline, and 202 with Alzheimer’s.

The scans covered 95 of the brain’s nearly 200 distinct regions and used an AI algorithm to predict patients’ health.

Being able to use AI to help diagnose Alzheimer’s earlier could give patients and doctors crucial time to prepare and potentially slow the progression of the disease.

The analysis showed that one of the top predictive factors was brain volume loss, or shrinkage, in the hippocampus, which helps form memories, the amygdala, which processes fear, and the entorhinal cortex, which helps provide a sense of time.

This pattern held across age and sex, with both men and women aged 69 to 76 showing volume loss in the right part of the hippocampus, suggesting it may be an important area for early diagnosis, the researchers noted.

However, the research also found that the way brain regions shrink differs by sex.

In females, volume loss occurred in the brain’s left middle temporal cortex, which is involved in language and visual perception. In males, it was mainly seen in the right entorhinal cortex

The researchers believe this could be linked to changes in sex hormones, including the loss of oestrogen in women and testosterone in men.

These conclusions could help improve methods of diagnosis and treatment going forward, Nephew said.

More than 7.2m Americans are living with Alzheimer’s, according to the Alzheimer’s Association.

More research is being done to reveal other impacting factors.

Nephew said: “The critical challenge in this research is to build a generalisable machine-learning model that captures the difference between healthy brains and brains from people with mild cognitive impairment or Alzheimer’s disease.”

Continue Reading

News

Vision implant firm raises US$230m

Published

on

A vision implant firm has raised US$230m as it seeks approval in Europe and the US for a device that restored sight in a small clinical trial.

The Alameda, California-based startup said the funding would support commercialisation of its Prima device.

It said an upcoming launch is planned in Europe and that it would become the first brain computer interface company to have a vision restoration device on the market.

A clinical trial in Europe found the small implant could work as artificial photoreceptors in the retina to restore functional central vision.

The implant is placed under the retina to replace the function of light-sensitive cells lost to disease. A special pair of glasses with an embedded camera and infrared projector sends light signals to the implant.

The study assessed the system in people with advanced dry age-related macular degeneration.

Of the 38 patients who received an implant, 32 were assessed at 12 months. Results showed the device led to a clinically meaningful improvement in visual acuity in 26 people.

The patients were able to read letters, numbers and words, according to the company.

Science Corporation said it has submitted a CE mark application to the European Union and applied to the US Food and Drug Administration for regulatory approval.

Darius Shahida, chief strategy officer, said: “Our imperative is to become the first BCI company to scale and achieve profitability.”

Founded in 2021, the company has now raised about US$490m in total. It said it is expanding its clinical trial programme to include other retinal diseases, such as Stargardt disease and retinitis pigmentosa.

The Series C round included existing investors Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT and Quiet Capital.

Science Corporation said demand for the round exceeded its capital needs, with funds also earmarked for expanding research, manufacturing infrastructure and operations.

Continue Reading

News

Radiology AI may improve workflows

Published

on

Radiology AI may improve workflows and patient care, but the technology also brings challenges for radiology departments, research suggests.

A focus issue from the Journal of the American College of Radiology brings together invited research and reviews exploring how AI is being used across different practice types.

Barriers include insufficient infrastructure, strict institutional regulations and a lack of insurance reimbursement, all of which can hamper the integration of AI into routine clinical workflows.

Radiology, the branch of medicine that uses imaging such as X-rays and scans to diagnose and treat disease, is widely seen as one of the fields most likely to be reshaped by AI.

The research includes contributions arguing that workflow improvement is not simply a secondary benefit of AI, but a main determinant of whether a tool succeeds.

Gelareh Sadigh, associate editor for health services research at the Journal of the American College of Radiology, said: “When thoughtfully implemented, AI can complement human expertise and improve efficiency and patient care.

“Successful workflow optimisation requires the integration of AI technology into routine workflows.

“This can be hampered by insufficient infrastructure, strict institutional regulations, and lack of insurance reimbursement.

“Poor integration of AI may degrade workflows, satisfaction, and safety and perpetuate bias in healthcare.”

According to Dr Sadigh, the articles in the focus issue reflect a broader shift in radiology: workflow is not a secondary benefit of AI, but a key factor in whether a tool is successful.

If AI is going to meaningfully help radiology, it must make care delivery better and not more complicated.

Ruth C. Carlos, editor-in-chief of the Journal of the American College of Radiology, said: “This focus issue provides meaningful signposts for AI effectiveness as we navigate a rapidly shifting landscape.”

Continue Reading

Trending

Agetech World